Evidence map›Paper›PMID 26395458›Full record

ArticleHuman molecular genetics2015

A role for repressive complexes and H3K9 di-methylation in PRDM5-associated brittle cornea syndrome.

Louise F Porter, Giorgio G Galli, Sally Williamson, Julian Selley, David Knight, Nursel Elcioglu, Ali Aydin, Mustafa Elcioglu, Hanka Venselaar, Anders H Lund and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Vascular phenotypes in nonvascular subtypes of the Ehlers-Danlos syndrome: a systematic review.Genetics in medicine : official journal of the American College of Medical Genetics · 2018
    Pooled it
  2. Article
  3. Article
  4. Review
  5. OiScience · 2024
    Article
  6. Article
  7. Review
  8. Case report of aIndian journal of ophthalmology · 2020
    Article
  9. Article
  10. Review
  11. Brittle cornea syndrome: current perspectives.Clinical ophthalmology (Auckland, N.Z.) · 2019
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 5 countries.

Louise F PorterCentre for Genomic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Science Centre (MAHSC), Manchester, UK, Manchester Royal Eye Hospital, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.
Giorgio G GalliStem Cell Program, Boston Children's Hospital, Harvard Stem Cell and Regenerative Biology Department and Harvard Stem Cell Institute, Harvard University, Boston, MA, USA, Biotech Research and Innovation Centre and Centre for Epigenetics, University of Copenhagen, Copenhagen, Denmark.
Sally WilliamsonCentre for Genomic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Science Centre (MAHSC), Manchester, UK.
Julian SelleyFaculty of Life Sciences, Michael Smith Building, Manchester, UK.
David KnightFaculty of Life Sciences, Michael Smith Building, Manchester, UK.
Nursel ElciogluDepartment of Pediatric Genetics, Marmara University Medical School, Istanbul, Turkey.
Ali AydinDepartment of Ophthalmology, University of Medipol Medical Faculty, Istanbul, Turkey.
Mustafa ElciogluDepartment of Ophthalmology, Okmeydani Research and Training Hospital, Istanbul, Turkey.
Hanka VenselaarCentre of Molecular and Biomolecular Informatics, Radboudumc Institute for Molecular Life Sciences, Nijmegen, The Netherlands and.
Anders H LundBiotech Research and Innovation Centre and Centre for Epigenetics, University of Copenhagen, Copenhagen, Denmark.
Richard BonshekManchester Royal Eye Hospital, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, National Ophthalmic Pathology Service Laboratory, Department of Histopathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Graeme C BlackCentre for Genomic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Science Centre (MAHSC), Manchester, UK, Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, MAHSC, Manchester, UK graeme.black@manchester.ac.uk.
Forbes D MansonCentre for Genomic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Science Centre (MAHSC), Manchester, UK.
Manchester Academic Health Science Centre · GBUniversity of Manchester · GBBoston Children's Hospital · USIstanbul Medipol University · TRMarmara University · TROkmeydanı Eğitim ve Araştırma Hastanesi · TRRadboud University Nijmegen · NLUniversity of Copenhagen · DK

Funding

Department of Health BRF-2011-015
6 · The paper itself

Abstract

Type 2 brittle cornea syndrome (BCS2) is an inherited connective tissue disease with a devastating ocular phenotype caused by mutations in the transcription factor PR domain containing 5 (PRDM5) hypothesized to exert epigenetic effects through histone and DNA methylation. Here we investigate clinical samples, including skin fibroblasts and retinal tissue from BCS2 patients, to elucidate the epigenetic role of PRDM5 and mechanisms of its dysregulation in disease. First we report abnormal retinal vascular morphology in the eyes of two cousins with BCS2 (PRDM5 Δ exons 9-14) using immunohistochemistry, and mine data from skin fibroblast expression microarrays from patients with PRDM5 mutations p.Arg590* and Δ exons 9-14, as well as from a PRDM5 ChIP-sequencing experiment. Gene ontology analysis of dysregulated PRDM5-target genes reveals enrichment for extracellular matrix (ECM) genes supporting vascular integrity and development. Q-PCR and ChIP-qPCR confirm upregulation of critical mediators of ECM stability in vascular structures (COL13A1, COL15A1, NTN1, CDH5) in patient fibroblasts. We identify H3K9 di-methylation (H3K9me2) at these PRDM5-target genes in fibroblasts, and demonstrate that the BCS2 mutation p.Arg83Cys diminishes interaction of PRDM5 with repressive complexes, including NuRD complex protein CHD4, and the repressive chromatin interactor HP1BP3, by co-immunoprecipitation combined with mass spectrometry. We observe reduced heterochromatin protein 1 binding protein 3 (HP1BP3) staining in the retinas of two cousins lacking exons 9-14 by immunohistochemistry, and dysregulated H3K9me2 in skin fibroblasts of three patients (p.Arg590*, p.Glu134* and Δ exons 9-14) by western blotting. These findings suggest that defective interaction of PRDM5 with repressive complexes, and dysregulation of H3K9me2, play a role in PRDM5-associated disease.

Indexed as

MutationAdultAntigens, CDCadherin 5CadherinsChildCollagenDNA-Binding ProteinsEhlers-Danlos SyndromeFemaleFibroblastsGene OntologyHistonesHumansMaleMethylationAntigens, CDCadherin 5CadherinsCollagenDNA-Binding ProteinsHistonesNerve Growth FactorsNetrin-1NTN1 protein, humanPRDM5 protein, humanTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID26395458
PMCPMC4634368
OpenAlexW1948892360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.